Table III.
Patient demographics and standardized assessment data.
| Patient ID | Sex | Age (years) |
MPO | Handedness | Lesion Volume (mm3) |
WAB AQ (/100) |
BNT (/60) |
PPT (/52) |
|---|---|---|---|---|---|---|---|---|
| Treated Patients (TxPWA) | ||||||||
| BU03 | F | 63 | 62 | R | 175,378 | 52.00 | 10 | 46 |
| BU04 | M | 79 | 13 | R | 84,778 | 74.10 | 52 | 49 |
| BU06 | M | 49 | 113 | R | 298,967 | 66.60 | 44 | 48 |
| BU07 | M | 55 | 137 | R | 181,973 | 48.00 | 6 | 46 |
| BU08c01* | M | 49 | 57 | R | 87,587 | 82.80 | 51 | 48 |
| BU09 | F | 71 | 37 | R | 11,660 | 95.20 | 45 | 50 |
| BU10 | F | 53 | 12 | R | 76,553 | 80.40 | 37 | 49 |
| BU11 | M | 78 | 22 | R | 32,114 | 92.10 | 41 | 49 |
| BU12 | M | 68 | 104 | R | 186,845 | 40.00 | 1 | 46 |
| BU13 | M | 42 | 18 | L | 12,131 | 92.70 | 43 | 49 |
| BU14 | F | 64 | 24 | R | 96,932 | 64.40 | 41 | 49 |
| BU15 | F | 71 | 74 | R | 189,309 | 87.20 | 43 | 44 |
| BU16co5* | M | 50 | 71 | R | 317,071 | 33.60 | 1 | 41 |
| BU17 | M | 61 | 152 | R | 163,488 | 74.30 | 54 | 51 |
| BU18 | F | 70 | 152 | R | 69,643 | 78.00 | 24 | 50 |
| BU19c02* | M | 80 | 22 | R | 89,026 | 28.90 | 1 | 43 |
| BU20 | F | 48 | 14 | R | 164,327 | 13.00 | 0 | 40 |
| BU21 | M | 65 | 16 | R | 247,593 | 11.70 | 0 | 43 |
| BU22 | M | 62 | 12 | R | 100,019 | 65.40 | 1 | 37 |
| BU23 | M | 60 | 24 | R | 172,812 | 45.20 | 6 | 42 |
| BU24c06* | M | 69 | 170 | R | 183,449 | 40.40 | 3 | 49 |
| BU25 | F | 76 | 33 | R | 184,390 | 37.50 | 2 | 34 |
| BU26 | F | 64 | 115 | R | 127,704 | 58.00 | 15 | 36 |
| BU27c08* | M | 65 | 17 | L | 34,148 | 84.30 | 41 | 50 |
| BU28 | M | 63 | 15 | R | 76,654 | 56.00 | 21 | 51 |
| BU30c11* | M | 59 | 29 | R | 186,520 | 60.00 | 16 | 48 |
| Mean | 62.8 | 58.3 | 136,579.7 | 60.1 | 23.4 | 45.7 | ||
| SD | 10.2 | 51.8 | 81100.4 | 24.0 | 20.2 | 4.8 | ||
| Untreated Patients (unPWA) | ||||||||
| BUc01 | M | 49 | 49 | R | 87,587 | 85.50 | 53 | 49 |
| BUc02 | M | 79 | 10 | R | 89,026 | 26.90 | 3 | 47 |
| BUc05 | M | 49 | 67 | R | 317,071 | 32.30 | 3 | 44 |
| BUc06 | M | 69 | 164 | R | 183,449 | 39.30 | 5 | 48 |
| BUc07NU | M | 39 | 17 | R | 26,221 | 71.30 | 36 | 52 |
| BUc08 | M | 64 | 13 | L | 34,148 | 79.60 | - | 50 |
| BUc09 | M | 62 | 21 | L | 1,565 | 91.50 | 39 | 49 |
| BUc10NU | M | 68 | 21 | R | 80,283 | 78.60 | 31 | 49 |
| BUc11 | M | 58 | 23 | R | 186,520 | 61.80 | 10 | 51 |
| BUc12 | M | 53 | 467 | R | 120,817 | 91.20 | 51 | 49 |
| Mean | 59.0 | 85.2 | 112,668.7 | 65.8 | 25.7 | 48.8 | ||
| SD | 11.8 | 141.9 | 94,592.8 | 24.6 | 20.6 | 2.2 | ||
*
Asterisks indicate patients enrolled in the treatment group after first completing all stages of the study as untreated patients. Subject IDs of patients who crossed over are appended with their ID from the untreated group (e.g., the first untreated control patient, BUc01, was enrolled in the treatment group as BU08c01; the second untreated patient, BUc02, was enrolled in the treatment group as BU19c02; etc.).
Abbreviations: MPO: Months post-onset of aphasia; WAB AQ: Western Aphasia Battery Aphasia Quotient; BNT: Boston Naming Test; PPT: Pyramids and Palm Trees test